Back to search
NSCLC, Non-small-cell Lung Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which NSCLC, Non-small-cell Lung Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which NSCLC, Non-small-cell Lung Carcinoma trials you may qualify forBackground: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are st…
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS…
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity)…
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating pat…
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surg…
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with l…
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal…
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive…